CHF Solutions Welcomes Industry Veteran Nestor Jaramillo as Chief Commercial Officer
May 06 2019 - 4:30PM
CHF Solutions (Nasdaq: CHFS) today announces it has hired Nestor
Jaramillo, Jr. as its new chief commercial officer, effective May
7, 2019.
“Nestor has been a key player in medical device
commercialization for more than 20 years and has led commercial
organizations in both startup and multinational companies,” said
John Erb, CEO of CHF Solutions. “With Nestor in place, we
look forward to enhancing our sales and marketing execution which
will drive our revenue growth.”
Prior to joining CHF Solutions, Mr. Jaramillo was president and
CEO of Innerspace Neuro Solutions, Inc., a Tustin, Calif.-based
commercial-stage medical technology company that developed,
manufactured and distributed an intracranial pressure monitoring
system. He also worked in a variety of capacities at startup
Transoma Medical, St. Jude Medical, and at Medtronic. In
addition, he also spent seven years as a managing director of
healthcare investment banking at both Cherry Tree & Associates
and Craig-Hallum Capital, both in Minneapolis. He holds an
engineering degree from the University of North Dakota and a Master
of Business Administration from the University of St. Thomas in
Minneapolis.
“I’m excited to work with an organization that is providing the
medical community a unique approach to fluid management with the
goal of improving clinical outcomes for patients, whether in the
hospital or outpatient clinic setting,” said Mr. Jaramillo. “CHF
Solutions is continually seeking new applications and venues for
the Aquadex FlexFlow® ultrafiltration system and I look forward to
working with the team to further expand our market presence and
provide this life-changing therapy to the many patients who
urgently need it.”
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company
focused on commercializing the Aquadex FlexFlow system for
aquapheresis therapy. The Aquadex FlexFlow system is indicated for
temporary (up to eight hours) ultrafiltration treatment of patients
with fluid overload who have failed diuretic therapy and extended
(longer than 8 hours) ultrafiltration treatment of patients with
fluid overload who have failed diuretic therapy and require
hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom
having received training in extracorporeal therapies. The company's
mission is to predict, measure, and control patient fluid balance
through science, collaboration, and innovative medical technology.
CHF Solutions is a Delaware corporation headquartered in
Minneapolis, Minnesota with wholly owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements relating to the company’s future sales and
marketing. Forward-looking statements are predictions, projections
and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS:Claudia Napal DraytonChief Financial
Officer CHF Solutions, Inc.952-345-4205ir@chf-solutions.com
-or-Bret Shapiro Managing Partner CORE
IR516-222-2560brets@coreir.com www.coreir.com
MEDIAJules Abraham JQA Partners, Inc.
917-885-7378jabraham@jqapartners.com
Source: CHF Solutions, Inc.
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024